How Does the Next Decade Look for the Global Mycoplasma Testing in Clinical Market?

According to the report "Mycoplasma genitalium Urethritis: Prevalence and Drug-Resistance Patterns" published in March 2020, Mycoplasma gentitalium is one of the leading causes of male urethritis, and according to a study conducted on a total of 914 participants, 28.7% of the population had Mycoplasma genitalium (MG) infection. According to the February 2019 news, Mycoplasma was isolated from the rectum and anal canal of Crohn's disease patients, implying that Mycoplasma is also responsible for prevalent gastrointestinal infections.

Access Full Report at https://databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Data Bridge Market Research analyses that the Mycoplasma Testing in Clinical Market which was USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. Highly sensitive PCR and qPCR were developed, increasing the specificity of testing for more than 90 mycoplasma species. The test includes a variety of goods such as readers, assays, instruments, kits, and reagents, all of which contribute to market growth. A huge number of market participants are involved in the production of devices and consumables used for the identification of various mycoplasma species, paving the way for market expansion.           

Rising number of chronic diseases is expected to drive the market's growth rate

Various infectious diseases are on the rise these days, owing to poor hygiene and a variety of other factors. Mycoplasma is known to cause a variety of diseases by attacking various bodily parts. Mycoplasma has been linked to urethritis, Crohn's disease, pneumonia, and neurological disease, among other things. Because mycoplasma is the major cause of many diseases, the necessity for clinical testing is growing in order to provide the appropriate treatment at the right time. As a result, the increasing number of diseases is driving the expansion of worldwide mycoplasma testing in the clinical market.

Report Scope and Market Segmentation

Segment Analysis:

Global mycoplasma testing in clinical market is categorized into four notable segments which are based on products, technique, disease area and end user.

• On the basis of products, the mycoplasma testing in clinical market is segmented into kits and reagents, instruments and services. In 2023, kits & reagents segment is expected to dominate the market with 54.31% market share because kits and reagents are repeatedly purchased as products for the detection of mycoplasma.
• On the basis of technique, the mycoplasma testing in clinical market is segmented into microbial culture techniques/direct assay, polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods. In 2023, microbial culture techniques/direct assay segment is expected to dominate the market with 36.42% market share because these techniques are cost effective and highly specific when a positive result is obtained.
• On the basis of disease area, the mycoplasma testing in clinical market is segmented into respiratory, urogenital, gastrointestinal, cardiovascular, musculoskeletal, and others. In 2023, the respiratory segment is expected to dominate the market with 36.37% because mycoplasma affects children & adults with mild to severe pneumonias.

The respiratory segment will dominate the disease area segment of the mycoplasma testing in clinical market

The respiratory segment will emerge as the dominating segment under disease area with approximately 37.00% market share. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

• On the basis of end user, the mycoplasma testing in clinical market is segmented into hospitals and diagnostics laboratories. In 2023, diagnostics laboratories segment is expected to dominate the market with 55.14% market share because diagnostics laboratories are fully equipped with all the products required for the detection of mycoplasma and presence of skilled professional.

The diagnostics laboratories segment will dominate the end user segment of the mycoplasma testing in clinical market

The diagnostics laboratories centers segment will emerge as the dominating segment end user segment. This is because of the growing number of diagnostics laboratories in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

Major Players

Data Bridge Market Research recognizes the following companies as the major market players: AB ANALITICA s.r.l. (Italy), bioMérieux SA (France), ELITechGroup (France), Liofilchem S.r.l. (Italy), Agilent Technologies, Inc. (U.S.), PromoCell GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), OSANG Healthcare (south Korea), Sacace Biotechnologies Srl (Italy), Lonza (Switzerland), Merck KGaA (Germany), Seegene Inc. (South Korea), Clongen Laboratories, LLC (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Charles River Laboratories (U.S.), Bionique Testing Laboratories, Inc. (U.S.) and ZEAKON Diagnostics (U.S.).

Market Development

• In 2023, SwiftDx debuted a new mycoplasma detection kit in February. SwiftDx Mycoplasma Detection Kit, which was recently released, provides a faster and more convenient solution for detecting mycoplasma contamination using a lateral flow test.
• In 2020, Merck KGaA expanded its manufacturing presence in the United States in December, investing more than USD 45.6 million (EUR 40 million) in its Massachusetts and New Hampshire production sites. The sites were designed to generate a variety of biopharmaceutical manufacturing goods while also increasing the company's production capacity.
• In 2020, Infinity Laboratories expanded its capabilities in April when it began offering Mycoplasma testing. The capacities of the top market players will improve as a consequence of the implementation of key strategies such as expansion, partnerships, acquisitions, and others, resulting in market expansion.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in the mycoplasma testing in clinical market during the forecast period 2023 to 2030

North America dominates the clinical mycoplasma testing market because to frequent purchases of consumables for mycoplasma detection in cell culture; the kits and reagents sector is also predicted to develop at the quickest rate.

Asia-Pacific is estimated to be the fastest growing region in the mycoplasma testing in clinical market in the forecast period 2023 to 2030

Given the rising need for effective testing, Asia-Pacific is predicted to develop at the fastest rate during the projection period of 2023 to 2030. The kits and reagents segment dominates the clinical market for mycoplasma testing. 

For more detailed information about the mycoplasma testing in clinical market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-mycoplasma-testing-in-clinical-market